Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the ...

Buyout firm Advent International is considering the sale of generic drugmaker Zentiva, in a deal that could value the former Sanofi unit at about €5 billion ($5.4 billion), according to people ...

The UWWTD will require manufacturers to fund micropollutant removal, but Zentiva says the financial squeeze could mean ...

Directive Might Cause Massive Medicine Shortages Affecting Millions Of Patients Across Europe ...

While customers at Adams Family Pharmacy picked up their prescriptions on a hot summer day, some stopped in for coffee, ice cream, homemade cake, or cookies.

Stroke rates in Californians with sickle cell disease (SCD) have increased in both children and adults in the post-STOP era. The cumulative incidence of first ischemic stroke was 2.1% by age 20 ...

Novo Nordisk is urging the U.S. Food and Drug Administration (FDA) to block ‘copycat’ versions of its popular weight-loss and diabetes drugs, arguing that the complexities of manufacturing ...

A self-proclaimed Brazil-Italy collaboration enthusiast, researcher Laura Bolognesi created the B2AlzD2 Joint Lab at the Department of Pharmacy and ... cell disease (SCD) who live in food deserts ...

When the one pharmacy in town closed in Antwerp, a small community of about 1,600 in northwest Ohio, in September, it affected Candace Pidgeon in two ways. The pharmacy tech lost her job at the ...

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain ... with hospitals to gain formulary access through the Pharmacy & Therapeutics process. Launch dynamics may ...

DTE Maharashtra Post HSC Diploma in Pharmacy Admission 2024: DTE Maharashtra is set to publish on its official website phd24.dtemaharashtra.gov.in today i.e. Wednesday October 16, 2024 CAP Round 1 ...

Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much urgency to start on these expensive therapies, said Kevin Niehoff ...